This is a working overview of peptide degradation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
== External links == Kristin Tillotson, "Minnesota Opera co-commissions Cold Mountain, Minneapolis Star Tribune (Artcetera blog), 6 May 2014 Heidi Waleson, "Creating Cold Mountain: Student Singers Help to Shape a Major Modern Opera", Overtones (Curtis Institute of Music), Spring 2014 Cold Mountain, Opera Philadelphia page "Cold Mountain makes East Coast Premiere February 5–14, 2016, at the Academy of Music." Opera Philadelphia press release, 5 January 2016 Tom Huizenga, "Great Expectations: A New Season Of New Music". National Public Radio (Deceptive Cadence blog), 3 September 2014 "Jennifer Higdon writes an opera", The Musicalist podcast, 12 February 2014 Jim Cotter, "Jennifer Higdon on Cold Mountain". WRTI, 90.1 FM, 16 November 2012 Mark Gresham, "Jennifer Higdon completes her new opera, Cold Mountain". EarRelevant blog, 17 September 2013 Pentatone Records page on Cold Mountain Peter Dobrin, "Cold Mountain scores", The Philadelphia Inquirer, Blogs the Arts, 16 May 2016
== Prison population == Thailand ranks seventh in the world in prison population per 100,000 citizens (1=highest prisoner rate; 221=lowest prisoner rate). Thailand jails 450 persons per 100,000 population. Other ASEAN nations, their world ranking, and their incarceration rates: Singapore ranked 63 (prisoner rate, 219); Malaysia, 85 (167); Vietnam, 102 (146); Philippines, 109 (140); Brunei, 116 (134); Laos, 134 (119); Cambodia, 136 (116); Myanmar, 141 (113); Indonesia, 167 (76). Despite its population of only about 70 million, its total prison population ranks sixth in the world.
inorganic ions (typically monitored as electrical conductivity or resistivity or specific tests) organic compounds (typically monitored as TOC or by specific tests) bacteria (monitored by total viable counts or epifluorescence) endotoxins and nucleases (monitored by LAL or specific enzyme tests) particulates (typically controlled by filtration) gases (typically managed by degassing when required)
=== Quantitative analysis === Quantitative approach requires large number of grain analyses within a sample rock in order to represent the overall detrital zircon population statistically (i.e. the total number of analyses should achieve an appropriate level of confidence). Because of the large sample size, secondary ion mass spectrometry (SIMS) and laser ablation-inductively coupled plasma mass spectrometry (LA-ICPMS) are used instead of thermal ionization mass spectrometry (TIMS). In this case, BSE and CL imagery are applied to select the best spot on a zircon grain for acquiring reliable age.
Sources: en.wikipedia.org
=== Characterization === Cox described Logan Roy as a "mysterious character in many ways. I have a lot of empathy for him. I think he's very misunderstood. I think he's a tragic figure", and compared him to Shakespeare's tragic kings, such as Henry IV. "Obviously there's Lear connotations, but it's also the father dealing with a child in his son Hal and not understanding him." David Rasche, who plays Karl Muller, suggested to Jesse Armstrong that his character became a confessor to Logan, "But I don't think Jesse wanted that. Jesse wanted Logan Roy, a man alone." Cox thinks of Logan as "quite Puritan [...] Logan's a bastard, but he's not an indecent bastard." On Logan's romantic relationships he has said "He clearly loves Marcia. There's this idea that he had this affair with Rhea, but I'm not sure that happened. Both Holly [Hunter] and I felt that hadn't actually happened, [...] The kids thinking they were having an affair was more them projecting", but also added that "he's not good at relationships at all. The female relationships in his life have been pretty disastrous". By the final season Cox noted that, Colin and Kerry, Logan's bodyguard and assistant respectively, were "the two people who matter to him most." Cox has expressed that he believes that Logan's greatest weakness was that "he loves his children desperately." In interviews with The New Yorker, Armstrong agreed with Cox that Logan loves his children, even if he had done "things which are antithetical to what most people would consider to be love."
== Veterinary medicine == HbA1c testing has not been found useful in the monitoring during the treatment of cats and dogs with diabetes, and is not generally used; monitoring of fructosamine levels is favoured instead.
Chloroformic acid is a chemical compound with the formula ClCO2H. It is the single acyl-halide derivative of carbonic acid (phosgene is the double acyl-halide derivative). Chloroformic acid is also structurally related to formic acid, in a way that the non-acidic hydrogen of formic acid is replaced by chlorine. Despite the similar name, it is very different from chloroform. It is described as unstable, decomposing into carbon dioxide and hydrogen chloride. Chloroformic acid itself is too unstable to be handled for chemical reactions. However, many esters of this carboxylic acid are stable and these chloroformates are important reagents in organic chemistry. They are used to prepare mixed carboxylic acid anhydrides used in peptide synthesis.
Other notable derivatives then result from further modification of this template, with saturation of the 7,8-double bond of etorphine resulting in the even more potent dihydroetorphine (up to 12,000× potency of morphine) and acetylation of the 3-hydroxy group of etorphine resulting in acetorphine (8700× morphine). While the isopentyl homologue of etorphine, known as M-140, is nearly three times more potent, its 7,8-dihydro and 3-acetyl derivatives are less potent than the corresponding derivatives of etorphine at 11,000 and 1300 times morphine, respectively. Replacing the N-methyl group with cyclopropylmethyl results in opioid antagonists such as diprenorphine (M5050, which is used as an antidote to reverse the effects of etorphine, M99), and partial agonists such as buprenorphine, which is widely used in the treatment of opioid addiction, although conversely the N-cyclopropylmethyl derivative of M-140, which has the code number M-320, retains similarly potent μ-opioid full agonist activity to the N-methyl derivative. More complex substitutions on the ring system can be used to produce selective δ-opioid agonists such as BU-48, and selective κ-opioid agonists such as CL 110,393.
The Great French Wine Blight was a severe blight of the mid-19th century that destroyed many of the vineyards in France and laid waste to the wine industry. It was caused by an insect that originated in North America and was carried across the Atlantic in the late 1850s. The actual genus of the insect is still debated, although it is largely considered to have been a species of Daktulosphaira vitifoliae, commonly known as grape phylloxera. While France is considered to have been worst affected, the blight also did a great deal of damage to vineyards in other European countries. How Phylloxera was introduced to Europe remains debated: American vines had been taken to Europe many times before, for reasons including experimentation and trials in grafting, without consideration of the possibility of the introduction of pestilence. While the Phylloxera was thought to have arrived around 1858, it was first recorded in France in 1863, in the former province of Languedoc. It is argued by some that the introduction of such pests as phylloxera was only a problem after the invention of steamships, which allowed a faster journey across the ocean, and consequently allowed pests such as the Phylloxera to survive the trip. Eventually, following Jules-Émile Planchon's discovery of the Phylloxera as the cause of the blight, and Charles Valentine Riley's confirmation of Planchon's theory, Leo Laliman and Gaston Bazille, two French wine growers, proposed that the European vines be grafted to the resistant American rootstock that were not susceptible to the Phylloxera.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.